Clearstead Advisors’s Erasca ERAS Stock Holding History

Clearstead Advisors’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$5	–	2903
2025 Q3	$5	Buy	+2	New	+$3	﹤0.01%	3063

Other funds holding ERAS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Clearstead Advisors's ERAS Position: Q4 2025 in Review

Clearstead Advisors sold out of Erasca (ERAS) in Q4 2025, closing a stake of 2 shares — an estimated $5 sold.

Clearstead Advisors first reported a position in ERAS in Q3 2025 and held it in 1 quarter. The position peaked at $5 in Q3 2025. 154 funds tracked by Wall St. Rank hold ERAS as of Q4 2025.

Clearstead Advisors reported no remaining Erasca position as of Q4 2025 after selling out during the quarter.
Clearstead Advisors sold 2 Erasca shares in Q4 2025, an estimated $5.
Clearstead Advisors first reported a position in Erasca in Q3 2025 and held it in 1 quarter.
Clearstead Advisors's Erasca position peaked at $5 in Q3 2025.
154 funds tracked by Wall St. Rank held Erasca as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.